AIDS Drug in Halted Trial Is Less Effective Taken Alone
March 13, 2003
The US National Institutes of Health halted the trial of GlaxoSmithKline's AIDS drug Trizivir after it proved less effective than when used in combination with another AIDS drug, the company said. A Glaxo spokesperson said the NIH's AIDS clinical trial conducted three studies in parallel, one of which tested patients taking just Trizivir. In two further studies, some patients took a combination of the Bristol-Myers Squibb Co. drug Sustiva with Trizivir, while others took a combination of Glaxo's drug Combivir with Sustiva. NIH decided to stop the Trizivir-only trial because only 74 percent of patients had a viral load of less than 200 after 48 weeks. In the other two trials, 89 percent of patients achieved a viral load of less than 200.Adapted from:
Wall Street Journal
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.